Xarelto (rivaroxaban)

pCPA File Number: 21080
Negotiation Status:
Concluded with an LOI
Indication(s):
Prevention of stroke and cardiovascular events in coronary and peripheral artery disease.
Sponsor/Manufacturer:
Bayer Inc.
CDA-AMC Project Number:
SR0569-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: